Randomised controlled trial
Extended Dual Antiplatelet Therapy for Multivessel Coronary Artery Disease
- Randomised controlled trial
- open-label
- 97 centres in China
Authors' conclusion
Among patients with multivessel coronary artery disease who were in stable condition 12 months after implantation of a drug-eluting stent, extending DAPT with clopidogrel and aspirin for an additional 12 months led to a lower risk of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke than continuing aspirin alone, without an increased risk of bleeding.
Study context
- Population
- Patients 18–75 years with multivessel CAD, free of major ischemic or bleeding events on dual antiplatelet therapy (DAPT) for 12 months after drug-eluting stent implantationmedian follow-up 34.3 months
- Participants
- 8,250 patients
- Comparison
- Extended DAPT vs aspirin monotherapy
- DAPTn = 4,125
- Aspirin monotherapyn = 4,125reference
- Primary endpoint
- CV death, nonfatal MI or nonfatal stroke
- Follow-up
- 36-month Kaplan-Meier cumulative incidence
Primary result
As reported in the abstract
36 months
Hazard ratio
0.82
95% CI 0.69–0.98
P = 0.03
Events by treatment group
DAPT vs Aspirin monotherapy
HR 0.82 (95% CI 0.69–0.98); P = 0.03
Safety
| Outcome | DAPT | Aspirin monotherapy | HR (95% CI) | P value | |
|---|---|---|---|---|---|
| Clinically relevant or major bleeding (BARC type ≥2), primary safety end point · 36 months | 1.4% | 1.5% | 0.89 (0.61–1.30) | P = 0.54 | |
| 0.512Hazard ratio (log scale) |
Original publication
Extended Dual Antiplatelet Therapy for Multivessel Coronary Artery Disease. N Engl J Med. Published 16 July 2026. doi:10.1056/nejmoa2517588
Summarised from the published abstract; every number is checked against it